Trials / Sponsors / MingSight Pharmaceuticals, Inc
MingSight Pharmaceuticals, Inc
Industry · 3 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma) | Phase 1 / Phase 2 | 2026-07-01 |
| Terminated | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) | Phase 1 / Phase 2 | 2023-02-06 |
| Terminated | A Study Of The Selective PKC-β Inhibitor MS- 553 Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma | Phase 1 / Phase 2 | 2018-05-25 |